MedPath

Prediction of Preeclampsia (PE) at 11-13 Week

Completed
Conditions
Pre-Eclampsia
Registration Number
NCT03554681
Lead Sponsor
Chiu Yee Liona Poon
Brief Summary

This is an international multicentre prospective cohort study to validate the Bayes theorem based algorithms for the screening of pre-eclampsia (PE) in the first-trimester of pregnancy.

Detailed Description

The investigators have previously constructed Bayes model in the first-trimester which combines maternal characteristics and medical history (Mat-CH) together with mean arterial pressure (MAP), uterine artery pulsatility index (PI), and serum placental growth factor (PlGF) with a plan to assess the predictive performance.

The reference standards will be PE defined according to the International Society for the Study of Hypertension in Pregnancy and the American College of Obstetricians and Gynecologists. The systolic blood pressure should be \>140 mm Hg and/or the diastolic blood pressure should be \>90 mmHg on at least two occasions four hours apart developing after 20 weeks' gestation in previously normotensive women and there should be proteinuria (\>300 mg in 24 hours or two readings of at \>2+ on dipstick analysis of midstream or catheter urine specimens if no 24-hour collection is available). In the absence of proteinuria, new onset of any of the following systemic findings: a) thrombocytopaenia (platelet counts \<100,000 ยตL); b) renal insufficiency (creatinine \>1.1 mg/dL or 2-fold increase in creatinine in the absence of underlying renal disease); c) abnormal liver function (ie, hepatic transaminase levels twice normal); d) pulmonary oedema; or e) cerebral or visual symptoms. Preterm-PE is PE that requires delivery before 37 weeks' gestation. If a participant fulfills the criteria for PE by one definition and not the other she will be considered to have developed PE.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
10935
Inclusion Criteria
  • Aged โ‰ฅ 18 years
  • Singleton pregnancy
  • Live fetus
  • Provide Informed and written consent in the official language of the country
Exclusion Criteria
  • Unable to provide written Informed consent learning difficulties or serious mental illness or an inability to understand spoken and written the official language of the country.
  • Multiple Pregnancy
  • Non-viable fetus (missed spontaneous abortion or stillbirth)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The false positive and true positive frequencies for screening for PE using the Bayes theorem based methodsAt delivery
Secondary Outcome Measures
NameTimeMethod
The false positive and true positive frequencies for screening of delivery of all-Small for Gestational Age (SGA) neonates and preterm-SGA neonates (delivery before 37 weeks), with or without PEAt delivery

Trial Locations

Locations (14)

Clinical Research Institute of Fetal Medicine PMC

๐Ÿ‡ฏ๐Ÿ‡ต

Osaka, Japan

First Affiliated Hospital of Kunming Medical University

๐Ÿ‡จ๐Ÿ‡ณ

Kunming, China

Kwong Wah Hospital

๐Ÿ‡ญ๐Ÿ‡ฐ

Hong Kong, Hong Kong

Toyama University Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Toyama, Toyama Prefecture, Japan

Mediscan Chennai

๐Ÿ‡ฎ๐Ÿ‡ณ

Chennai, Tamil Nadu, India

KK Women's and Children's Hospital

๐Ÿ‡ธ๐Ÿ‡ฌ

Singapore, Singapore

Siriraj Hospital

๐Ÿ‡น๐Ÿ‡ญ

Bangkok, Thailand

Affiliated hospitals within The Japan Society for the Study of Hypertension in Pregnancy (JSSHP)

๐Ÿ‡ฏ๐Ÿ‡ต

Tokyo, Japan

Showa University Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Tokyo, Japan

National University Hospital

๐Ÿ‡ธ๐Ÿ‡ฌ

Singapore, Singapore

Taipei Chang Gung Memorial Hospital

๐Ÿ‡จ๐Ÿ‡ณ

Taipei, Taiwan

Chulalongkorn University Bangkok

๐Ÿ‡น๐Ÿ‡ญ

Bangkok, Thailand

Nanjing Drum Tower Hospital

๐Ÿ‡จ๐Ÿ‡ณ

Nanjing, China

Prince of Wales Hospital

๐Ÿ‡ญ๐Ÿ‡ฐ

Hong Kong, Hong Kong

ยฉ Copyright 2025. All Rights Reserved by MedPath